SCHEMBL3269455

SCHEMBL3269455

Cc1ccc(C(=CCSc2ccc(OCC(=O)O)c(Br)c2)c2ccc(C)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.72
PKM P14618 1/20 0.46
PPARA Q07869 1/20 0.43
POLB P06746 1/20 0.42
DUSP3 P51452 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
PTPN11 Q06124 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTGDR2 Q9Y5Y4 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274236 0.97 PPARD (0.69) PPARDPKMPPARAPOLBDUSP3
SCHEMBL3274240 0.97 PPARD (0.69) PPARDPKMPPARAPOLBDUSP3
SCHEMBL3269309 0.91 PPARD (0.79) PPARDPKMPPARAPOLBL3MBTL1
SCHEMBL3270467 0.89 PPARD (0.67) PPARDPKMPPARAKMT2APTGDR2
SCHEMBL3275119 0.89 PPARD (0.67) PPARDPKMPPARAKMT2APTGDR2
SCHEMBL3269862 0.89 PPARD (0.66) PPARDPKMPPARAPOLBKMT2A
SCHEMBL3271493 0.89 PPARD (0.72) PPARDPKMPPARAPTGDR2TSHR
SCHEMBL3269960 0.89 PPARD (0.66) PPARDPKMPPARAPOLBKMT2A
SCHEMBL3270859 0.88 PPARD (0.83) PPARDPPARA
SCHEMBL3269647 0.88 PPARD (0.63) PPARDPKMPPARAKMT2APTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP claimed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US claimed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP claimed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US claimed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO claimed
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP disclosed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US disclosed
EP-1558572-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2005-08-03 EP disclosed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US disclosed
WO-2004037776-A2 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS NOVO NORDISK A/S (DK) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070583-A1 Novel compounds, their preparation and use PPARG, PPARD, PPARA PPARD 2/4885PKM 697/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.